In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.

@article{Voitenleitner2013InVC,
  title={In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.},
  author={Christian Voitenleitner and Renae M. Crosby and Jill T Walker and Katja S. Remlinger and Jessica J Vamathevan and Amy Xiao Min Wang and Shihyun You and John J X Johnson and Ermias Woldu and Stephanie A Van Horn and Joseph Horton and Katrina L. Creech and J Brad Shotwell and Zhi Hong and Robert K. Hamatake},
  journal={Antimicrobial agents and chemotherapy},
  year={2013},
  volume={57 11},
  pages={5216-24}
}
GSK2485852 (referred to here as GSK5852) is a hepatitis C virus (HCV) NS5B polymerase inhibitor with 50% effective concentrations (EC50s) in the low nanomolar range in the genotype 1 and 2 subgenomic replicon system as well as the infectious HCV cell culture system. We have characterized the antiviral activity of GSK5852 using chimeric replicon systems with NS5B genes from additional genotypes as well as NS5B sequences from clinical isolates of patients infected with HCV of genotypes 1a and 1b… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Creech In Vitro Characterization of GSK2485852 November 2013 Volume 57 Number 11 aac.asm.org 5223 on S etem er 13, 2015 by gest httpaac.asm .rg/ D ow nladed fom

  • J Bechtel, R Crosby, A Wang, E Woldu, S Van Horn, J Horton
  • J. Hepatol. 54:S307
  • 2013
3 Excerpts

In vitro profiling of GSK 2336805 , a potent and selective inhibitor of HCV NS 5 A

  • LH Carballo, C Voitenleitner, +5 authors R Hamatake
  • J . Hepatol .
  • 2013

Analysis of HCV NS 5 B genetic variants following monotherapy with HCV796 , a nonnucleoside polymerase inhibitor , in treatmentnaive HCVinfected patients

  • SA Villano, AY Howe, D Rabile, D Harper, J Speth, G Bichier
  • Hepatology
  • 2012

Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients. Hepatology 44:607A– 608A

  • SA Villano, AY Howe, D Rabile, D Harper, J Speth, G. Bichier
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…